Melanocortin Receptor Modulators for Topical Skin Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Developing compounds that selectively modulate melanocortin receptors, particularly MC1-R, for therapeutic use in treating pigmentary disorders, inflammatory conditions, and immune disorders is challenging due to the difficulty in achieving high specificity and minimizing systemic exposure and side effects.
Innovation Solution
Synthesis of novel compounds of general formula (I) with specific physicochemical properties that allow for topical administration, enabling rapid and directed action on melanocortin receptors, reducing the amount of active agent required and minimizing systemic exposure, thereby reducing side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If systemic administration of melanocortin receptor modulators is used, then therapeutic effect is achieved, but systemic exposure and side effects increase
Solution Approach 1:
The patent applies local quality by designing compounds with specific physicochemical properties (log D at pH 6.5 ≥ 3, half-life ≤ 10 minutes) that enable selective accumulation at the skin target site. The compounds are formulated for topical administration, creating a localized therapeutic effect at the application site while minimizing systemic absorption and associated side effects.
2Reliability
If conventional administration methods are used, then therapeutic effect is achieved, but the amount of active agent required increases
Solution Approach 1:
The patent applies parameter changes by optimizing the physicochemical parameters of the compounds, specifically setting log D at pH 6.5 ≥ 3 and half-life ≤ 10 minutes. These parameter modifications enable enhanced skin penetration and rapid action, reducing the quantity of active agent needed to achieve therapeutic effect while minimizing systemic exposure.
3Measurement precision
If high specificity towards particular receptor subtypes is achieved, then therapeutic precision is improved, but compound design complexity increases
Solution Approach 1:
The patent applies parameter changes by establishing specific physicochemical criteria (log D at pH 6.5 ≥ 3, half-life ≤ 10 minutes) that inherently confer MC1-R selectivity. By optimizing these parameters, the compounds achieve high receptor subtype specificity without requiring complex design processes, as the physicochemical properties themselves guide the selectivity.
Data Source
AI summary
Melanocortin receptor modulators, processes for preparing them and use thereof in human medicine and cosmetics are described. Melanocortin receptor modulators corresponding to formula (I):compositions containing them, processes for their preparation and their use in pharmaceutical or cosmetic compositions are also described.